" "
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

KineMed Announces Agreement With MedImmune

Published: Wednesday, May 22, 2013
Last Updated: Wednesday, May 22, 2013
Bookmark and Share
Research will utilize Kinemed technology to study protein dynamics related to neurodegenerative diseases.

KineMed Inc. announced an agreement with MedImmune, the global biologics research and development arm of AstraZeneca, to study how a monoclonal antibody affects the dynamics of the cellular prion protein (PrPc).

Cellular prion protein is found in healthy people, but this protein is known to have altered conformation and function in several neurodegenerative conditions including Creutzfeldt–Jakob disease and fatal familial insomnia. Recent research has also demonstrated that the prion protein may be a key component of Alzheimer's disease. KineMed’s platform technology will allow MedImmune to track the prion protein, providing insight into how an antibody directed at PrPc will affect the turnover and expression of the protein at the cell surface.

“We are very pleased to work with MedImmune in the search for new and effective treatments for neurodegenerative diseases,” said Dr. Ravi Kiron, Chief Business Officer of KineMed. “The growing toll of neurodegenerative disease in the aging global population is an enormous burden for patients, healthcare providers, and healthcare systems world-wide. KineMed is committed to partnering with innovative biotech companies like MedImmune to help accelerate the discovery and approval of new and effective therapies for neurodegenerative disease.”

The MedImmune scientists working on this project are part of the AstraZeneca Neuroscience Innovative Medicines Unit.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,900+ scientific posters on ePosters
  • More Than 4,200+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

KineMed, Pfizer Launch Collaboration
KineMed has announced that it has entered into a strategic collaboration with Pfizer to discover and develop novel proprietary biomarkers in various fields of unmet medical need.
Tuesday, January 05, 2016
KineMed, CHDI Foundation Extend Huntington’s Disease Collaboration
Collaboration utilizes KineMed’s translational biomarker platform to characterize and track the pathogenesis of Huntington’s disease.
Friday, May 23, 2014
KineMed and Amgen to Develop Kinetic Biomarkers of Brain Proteinopathies
KineMed’s biomarker platform will allow Amgen to track synthesis and clearance rates of pathogenic proteins in the brain that drive neurodegeneration.
Tuesday, October 15, 2013
Pfizer-KineMed Collaboration Extends to Target Novel Diabetes Pathways
KineMed Inc. announced the renewal of a non-exclusive research collaboration with Pfizer Inc. for the advancement of novel approaches towards metabolic disease, in particular Type II Diabetes.
Thursday, March 28, 2013
The Michael J. Fox Foundation Extends Funding for KineMed’s Brain-Process Biomarker Research for PD
KineMed receives $1.2 Million reinvestment from The Michael J. Fox Foundation for the further development of kinetic biomarkers predictive of Parkinson’s disease changes ahead of symptoms.
Friday, June 29, 2012
KineMed and CHDI Foundation Collaborate
KineMed’s isotopic labeling technology and analytical expertise will be applied to measure in vivo production rates of huntingtin protein as a potential biomarker of disease state.
Thursday, May 17, 2012
KineMed to Collaborate with Merck KgaA to Validate new Applications for Drug Development Candidates
Technology to be applied to both clinical- and preclinical-stage compounds in Merck KGaA pipeline.
Tuesday, August 28, 2007
Scientific News
Breaking Cell Barriers with Retractable Protein Nanoneedles
Adapting a bacterial structure, institute researchers have developed protein actuators that can mechanically puncture cells.
Retractable Protein Nanoneedles
The ability to control the transfer of molecules through cellular membranes is an important function in synthetic biology; a new study from researchers at Harvard’s Wyss Institute for Biologically Inspired Engineering and Harvard Medical School (HMS) introduces a novel mechanical method for controlling release of molecules inside cells.
Leukemia’s Surroundings Key to its Growth
Researchers at The University of Texas at Austin have discovered that a type of cancer found primarily in children can grow only when signaled to do so by other nearby cells that are noncancerous.
Common Cell Transformed into Master Heart Cell
By genetically reprogramming the most common type of cell in mammalian connective tissue, researchers at the University of Wisconsin—Madison have generated master heart cells — primitive progenitors that form the developing heart.
‘Smelling’ Prostate Cancer
A research team from the University of Liverpool and the University of the West of England (UWE Bristol) has reached an important milestone towards creating a urine diagnostic test for prostate cancer that could mean that invasive diagnostic procedures that men currently undergo eventually become a thing of the past.
Genetic Mutation that Prevents Diabetes Complications
The most significant complications of diabetes include diabetic retinal disease, or retinopathy, and diabetic kidney disease, or nephropathy. Both involve damaged capillaries.
A Crystal Clear View of Biomolecules
Fundamental discovery triggers paradigm shift in crystallography.
Could the Food we Eat Affect Our Genes?
Almost all of our genes may be influenced by the food we eat, according to new research.
NIH Seeks Research Applications to Study Zika in Pregnancy, Developing Fetus
Institute has announced that the new effort seeks to understand virus effect on reproduction and child development.
Iron in the Blood Could Cause Cell Damage
Concentrations of iron similar to those delivered through standard treatments can trigger DNA damage within 10 minutes, when given to cells in the laboratory.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,200+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!